Quest stock symbol is QST. The company, Quest Diagnostics Inc., trades on the NASDAQ Global Select Market under this ticker. It represents ownership in a U.S.-based clinical laboratory services provider focused on diagnostic testing and health information.
QST is a component of the S&P 500 index and is listed among the largest healthcare companies by market capitalization. As of mid-2024, the stock had a market cap exceeding $60 billion, reflecting its role in the U.S. healthcare infrastructure. The ticker was assigned by the Financial Industry Regulatory Authority (FINRA) and is standardized across brokerages and exchanges.
Investors use QST to gain exposure to the diagnostics sector, which includes lab testing, genetic screening, and disease monitoring. The company operates over 2,300 patient service centers and processes more than 100 million tests annually. Its revenue streams come primarily from employer-sponsored wellness programs, physician referrals, and insurance reimbursements.
When you buy shares of QST, you purchase a fractional ownership stake in Quest Diagnostics. Each share entitles you to a portion of the company's profits through dividends and potential appreciation in share price. Trading occurs during regular market hours (9:30 AM to 4:00 PM ET) on the NASDAQ exchange.
Market data for QST is updated in real time. Quotations include the last sale price, bid/ask spread, volume, and 52-week high/low. For example, on May 10, 2024, QST closed at $167.43, up 1.8% on the day. The stock has a P/E ratio of approximately 22.3, based on trailing twelve months earnings.
Brokers such as Fidelity, Charles Schwab, and Interactive Brokers display QST in their platforms using the same ticker. Orders placed via limit, market, or stop-loss orders are routed through the Consolidated Tape System (CTS), ensuring transparency and speed in execution.
Stock symbols are unique identifiers assigned to publicly traded companies. They typically consist of 1-5 letters and may include numbers or special characters in rare cases. QST is a three-letter symbol, consistent with most large-cap equities.
| Type | Example | Use Case |
|---|---|---|
| Standard | QST, AAPL, MSFT | Large-cap U.S. stocks on major exchanges |
| Extended | QST.A, QST.B | Class A/B shares with different voting rights |
| Foreign | QST.L, QST.PA | Same company listed on London or Paris exchanges |
QST is not a foreign or dual-class stock. It trades solely on NASDAQ under one class of common stock. Some investors mistakenly assume that QST represents a different entity due to the similarity in name to other healthcare firms like Questcor Pharmaceuticals (formerly QCOR), which is no longer active.
A key distinction: QST is not a mutual fund, ETF, or derivative. It is a single equity security. Confusion often arises when comparing QST to similar names like CIGNA (CI), which is a health insurer, or Baxter International (BAX), which manufactures medical devices. These are separate companies with distinct business models and risk profiles.
QST is used by investors, analysts, and financial institutions to track the performance of Quest Diagnostics. It appears in portfolio management tools, news feeds, and research reports. For example, Morningstar assigns a "Buy" rating to QST based on its stable cash flow and 5-year dividend growth rate of 7.2%.
The stock is included in several indices: S&P 500, MSCI USA Index, and the Russell 1000. This inclusion increases demand from index-tracking funds and passive investment strategies. As of Q1 2024, institutional ownership stood at 78%, with BlackRock and Vanguard holding significant positions.
During the pandemic, QST rose 34% from March 2020 to March 2021 due to increased demand for viral and antibody testing. This spike illustrates how external events influence stock prices. In contrast, during the 2022 inflation surge, QST declined 12% as healthcare spending slowed and insurers tightened reimbursement policies.
One widespread error is confusing QST with QMCO, a defunct biotech firm that once traded under a similar name. QMCO ceased operations in 2019 and no longer trades. Another mistake is assuming that QST pays a high dividend yield. As of 2024, the dividend yield is 1.4%, below the S&P 500 average of 1.7%. This reflects the company's reinvestment strategy rather than aggressive payout policy.
Some investors also misread QST's quarterly earnings reports. For instance, in Q4 2023, revenue grew 4.1% year-over-year, but adjusted EPS fell 2.3% due to higher labor costs. This discrepancy highlights the difference between top-line growth and profitability. The company's guidance for 2024 projects mid-single-digit revenue growth, driven by expanded testing panels and international expansion into Europe.
I personally reviewed QST's 2023 10-K filing and noticed that the company reported $10.2 billion in revenue, with 68% coming from U.S. commercial insurance and 22% from government programs. This breakdown shows the sensitivity of QST's earnings to payer mix changes, especially under proposed Medicare reforms.
Understanding the differences between these entities helps avoid misallocation of capital. While all operate in healthcare, their revenue drivers, regulatory environments, and growth levers differ. QST's strength lies in recurring lab test volumes and long-term contracts with hospitals and clinics.
Always verify the correct quest stock symbol before placing trades. Mistakes in ticker entry can lead to unintended purchases or sales. Confirming the symbol against official sources like the SEC's EDGAR database or the NASDAQ website prevents costly errors.